Skip to main content
  • Modulation of U87 Glioma Stem Cells Using a Small Molecule Wnt Inhibitor

    Final Number:

    James B Lin BS; D. Cory Adamson MD PhD MPH MHSc

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Glioblastoma multiforme (GBM) is a rare but aggressive primary brain tumor. Its dismal prognosis and high rates of recurrence have been in part attributed to the presence of glioma stem cells (GSCs). While many studies have been done on the signaling pathways, including the Wnt pathway, of these GSCs, there has not been a viable small molecular inhibitor that targets this subpopulation of cells. Our study aims to explore the use of a novel small molecule Wnt inhibitor, C59, to target GSCs.

    Methods: We subjected U87 cells to increasing concentrations (0-200nM) of C59 for 48 and 72h, and quantified the effect of the drug by measuring the number of tumorspheres per field (at 40X) and the average diameters of these tumorspheres. Changes in proliferation were subsequently quantified using the MTT assay. Finally, treated cells were analyzed using flow cytometry for changes in proliferation and apoptotic levels with BrdU and Annexin V as markers respectively.

    Results: At 72h, the number of tumorspheres formed per field and the average diameter of the tumorspheres both showed a dose-dependent decrease (both P<0.001). The MTT assay also showed a significant (P<0.001) decrease in proliferation at 72h for C59 concentrations greater than or equal to 100nM, which was supported by flow cytometry analyses of BrdU incorporation (P<0.05). Interestingly we saw a concurrent increase in early apoptosis (P<0.05) measured by flow cytometry.

    Conclusions: Our results showed that treatment of U87 GSCs with 100nM of C59 for 72h is sufficient to decrease tumorsphere formation, both in number and size. This decrease could be attributed to a combined effect of decreased proliferation and increased apoptosis of the GSCs through inhibition of the Wnt pathway. Together, these findings suggest a potential for C59 to be used as a small molecule inhibitor for GSCs.

    Patient Care: My research will validate the potential of C59 as a treatment option to target GSCs.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the importance of a small molecule Wnt inhibitor in GSCs, 2) Discuss, in small groups, approaches to targeting GSCs, 3) Identify an effective adjuvant treatment for GBM.


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy